Metamistad (Metamizole Sodium Monohydrate)

Metamizole Sodium Monohydrate blocks cyclooxygenase enzymes, which reduces the synthesis of prostaglandins—key mediators of inflammation, pain, and fever. By lowering prostaglandin levels, it diminishes peripheral pain signalling and also exerts central analgesic and antipyretic actions within the spinal cord.

The appropriate dose of Metamistad is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual health factors. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for Metamizole Sodium Monohydrate in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing women.

To request Metamistad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamistad belongs to the pyrazolone class, offering potent analgesic and antipyretic effects that are generally stronger than non‑steroidal anti‑inflammatory drugs such as ibuprofen. However, it carries a higher risk of serious hematologic reactions, so clinicians select it when a more powerful option is needed and monitor patients closely.

Metamistad should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Metamistad is administered orally in the form supplied by the manufacturer. The tablet or liquid is taken with water, following the prescriber’s dosing schedule. Patients should not crush or chew extended‑release formulations unless specifically instructed.

The most serious adverse events linked to Metamistad include agranulocytosis, a potentially life‑threatening drop in white blood cells, severe allergic reactions such as anaphylaxis, and rare but serious skin conditions like Stevens‑Johnson syndrome. Immediate medical attention is required if any of these symptoms appear.

Metamistad should be avoided in patients with known hypersensitivity to pyrazolones, those with a history of severe blood dyscrasias, and individuals currently taking other NSAIDs or anticoagulants without medical supervision. Caution is also advised for patients with significant renal or hepatic impairment.